

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

DATE MAILED: 10/19/2006

		•			
Γ	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
	10/049,587 02/12/2002		Douglas E. Brenneman	15280W-0021US	9701
	759	00 10/19/2006		EXAM	INER
	Annette S Pare	nt	•	STANDLEY,	STEVEN H
		ownsend and Crew		Apribur	DA DED AND ADED
	Two Embarcade	ro Center 8th Floor	•	ART UNIT	PAPER NUMBER
	San Francisco, (CA 94111-3834		1649	

Please find below and/or attached an Office communication concerning this application or proceeding.

' ''		Application No.	Applicant(s)				
	Office Action Occurren	10/049,587	BRENNEMAN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Steven H. Standley	1649				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) 又	Responsive to communication(s) filed on 10 August 2006.						
•—		action is non-final.					
′=	Since this application is in condition for allowar		secution as to the merits is				
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims	•					
4) 🖂	Claim(s) <u>1-80</u> is/are pending in the application.						
•	4a) Of the above claim(s) 7,10-41 and 54-80 is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>1-6,8,9 and 42-53</u> is/are rejected.						
	Claim(s) is/are objected to.						
8)□	8) Claim(s) are subject to restriction and/or election requirement.						
Applicati	ion Papers						
9)☐ The specification is objected to by the Examiner. 10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
ات(۱۰	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.05(a).						
11)	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
,							
•	under 35 U.S.C. § 119		·				
	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)	☐ All b)☐ Some * c)☐ None of:						
	 Certified copies of the priority documents have been received. 						
	2. Certified copies of the priority documents						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
	application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date							
	mation Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P					
. —	er No(s)/Mail Date <u>8/06</u> .	6) Other:					
C. Detect and T	rademark Office						

Art Unit: 1649

DETAILED ACTION

Response to Amendment

The amendment filed 8/10/06 has been made of record. The text of those

sections of Title 35, U.S. Code, not included in this action can be found in a prior office

action. Claims 1-6, 8-9, and 42-53 are under consideration. Applicant is reminded that

now claims 46-52 are directed to non-elected species (ADNFIII plus ADNFI). See the

objection on page 3 (number 4) of the prior office action.

Objections/Rejections: Withdrawn

Specification

Objection to the specification for embedded hyperlinks is withdrawn due to

applicant's amendment.

Claim Objections

Objection to claim 5 is withdrawn due to applicant's amendment.

Objections/Rejections: Maintained/New Grounds

Claim Objections

Objection to claims 46-52 is maintained for the reasons made of record in the

office action dated 3/14/06. Applicant's arguments have been fully considered and not

found to be persuasive. Applicant argues the claims have been amended. This is not

found persuasive because claims 46-52 are to mixtures of ADNFI and ADNFIII, which

Art Unit: 1649

was not the elected invention. The elected invention is group I, wherein group I is directed to ADNF I and a method of reducing neuronal cell death by administration of ADNFI.

Claim Rejections - 35 USC § 103

Rejection of claims 1-6, 8-9, and 42-53 under 35 USC § 103(a) is maintained for the reasons made of record in the office action dated 3/14/06. Applicant's arguments have been fully considered and not found to be persuasive. Applicant argues that the examiner has failed to provide a reasonable expectation of success and motivation to combine the references. In particular, Applicant argues on page 16 of Remarks that Goodman et al teach away from the use of D-amino acids in an active portion of a conjugate (col 10, lines 31-38). This is not found persuasive because Goodman et al is not teaching that the D-amino acids in the carrier are responsible for inhibiting the active portion of a conjugate. In fact, Goodman teaches that D- or L- amino acids can be used in the carrier, but that the D-forms confer greater resistance to proteolytic activity. Goodman et al is simply saying the carrier could sterically mask or inhibit the active portion of the molecule. That applies to both D- and L- forms of a carrier conjugate. Thus, Goodman et al does not teach away from using D-amino acid substitutions.

Applicant further argues that a post filing date publication by the instant inventors (exhibit 1) suggests substitution from all L- to all D- was expected to yield an inactive form, but instead yielded an active form of ADNF. This is not found to be persuasive because the state of the art at around the time of filing was that substitution of D- for L-

Art Unit: 1649

amino acids in a short polypeptide can and does result in polypeptides with the activity of the L- forms. For instance, Rozhavskaya-Arena et al (2000) found that substituting D- for L- amino acids in a 7-mer (OB3) resulted in many active forms of a synthetic leptin agonist, with various activity levels, that contained one or more D-amino acids. See Table 4, page2504, and Figure 2, same page. Thus, it is simply a matter of routine testing to determine which substitutions will yield what activities. One of ordinary skill in the art would have had a very high expectation of success.

Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/049,587

Art Unit: 1649

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Steven H. Standley whose telephone number is (571) 272-3432. The examiner can normally be reached on 8:00-4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Janet Andre can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Steven Standley, Ph.D.

10/12/06

SUPERVISORY PATENT EXAMINER

Page 5